Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of MRD testing has increased in recent years. MRD can indicate the depth of response to treatment as well as patient outcomes, leading to suggestions of using MRD status to guide the treatment of patients with myeloma.
In this podcast, you will hear from Meral Beksac, MD, Ankara University, Ankara, Turkey, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, and Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, who discuss the exciting potential applications of MRD in multiple myeloma and share insights from recent clinical trials.
The MDS Sessions: Giants in MDS
Latest therapies in AML: IMGN632, magrolimab & gilteritinib
VJSession: EBMT/EHA CAR-T Nursing Session
The Myeloma Sessions: key updates from ASH 2020
The MPN Sessions: Rapidly advancing genomic discoveries and treatment strategies in MPNs
Updates for the management of MDS from ASH 2020
The AML Sessions: highlights from ASH 2020
The MDS Sessions: treating MDS around the world
Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data
Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020
Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights
Advances in CAR T-cell therapies for lymphoma from ASH 2020
Moving forward in MPN: timing driver mutations and novel therapies from ASH 2020
The MDS sessions: lower-risk disease
The AML Sessions: FLT3-mutated disease
The Lymphoma Sessions: highlights from iwNHL 2020
The MDS sessions: clinical trial participation, endpoints & approvals
The AML sessions: venetoclax-based regimens
The AML Sessions: IDH inhibitors
The AML sessions: advances in immuno-oncology from SOHO 2020
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive